Que es el guidance MIST?

Metabolites In Safety Testing. ICH M3 guidance que establece cuando los metabolitos humanos mayores necesitan evaluacion de seguridad. Metabolitos >10% de exposicion de farmaco padre requieren consideracion. Si toxicologia en animales no cubre, puede requerir estudios especificos.

Como se identifica un metabolito activo?

Mediante testing de actividad biologica. Fracciones de plasma o muestras de pacientes se testean en el mismo ensayo que el farmaco padre. Si muestran actividad, se aísla y caracteriza el metabolito responsable. Se cuantifica su contribucion al efecto terapeutico.

Por que DPP-4 es problematica para algunos peptidos?

DPP-4 remueve dipeptidos del N-terminus de peptidos con Pro o Ala en posicion 2. GLP-1 y GIP son sustratos naturales, por lo que se degradan rapidamente. Para agonistas de GLP-1, la resistencia a DPP-4 es requisito para efecto terapeutico sostenido.

Que es un estudio de mass balance?

Estudio que administra farmaco radiomarcado (tipicamente C14) para rastrear distribucion, metabolismo y excrecion completa. Permite identificar todos los metabolitos y routes de eliminacion. Requerido para NDA. Confirmar que no hay acumulacion de metabolitos desconocidos.

Metabolismo In Vivo de Peptidos

Categorías: Metodología de Investigación, Información General

El metabolismo in vivo determina el destino de los peptidos en el organismo. Comprenderlo es esencial para desarrollo terapeutico.

Resumen Simplificado

Las proteasas, peptidasas y sistemas metabolicos transforman peptidos, generando metabolitos activos o inactivos.

Sitios de metabolismo

Metabolism occurs throughout body. Blood. Plasma proteases. DPP-4. ACE. NEP. Many others. Rapid degradation. For many peptides. Liver. First-pass. Hepatic uptake. Intracellular degradation. CYP involvement. Rare for peptides. Renal. Glomerular filtration. Proximal tubule. Brush border enzymes. Peritubular uptake. Major clearance route. For smaller peptides. Tissues. Target tissues. Receptor-mediated uptake. Intracellular degradation. Local metabolism. At site of action. Cellular uptake. Endocytosis. Lysosomal degradation. Proteasome. Intracellular peptidases. Distribution affects. Where metabolism occurs. Large peptides. Less renal. More hepatic. Tissue uptake. Small peptides. Renal dominant. Rapid clearance. Understanding sites. Guides design. For desired PK. Site-specific metabolism. Can be exploited. Or avoided. Depends on goal. Prodrug strategies. Activate at target. Site-selective metabolism.

Enzimas metabolicas

Multiple enzymes metabolize peptides. Exopeptidasas. Aminopeptidasas. N-terminal. Aminopeptidase N. APN. Aminopeptidase A. APA. Remove N-terminal residues. Carboxipeptidasas. C-terminal. Carboxypeptidase N. CPN. Remove C-terminal residues. Endopeptidasas. Internal cleavage. Neprilysin. NEP. Multiple substrates. Insulin-degrading enzyme. IDE. Specific. Matrix metalloproteases. MMPs. Extracellular. Dipeptidyl peptidases. DPP-4. Removes dipeptides. From N-terminus. Major for incretins. Prolyl oligopeptidase. POP. Proline-specific. Angiotensin-converting enzyme. ACE. Converts Ang I to Ang II. Cathepsins. Lysosomal. Intracellular degradation. Tissue-specific. Different expression. Different activities. Enzyme distribution. Affects metabolism. Pattern. Rate. Organ specificity. Understanding enzymes. Enables prediction. Of metabolic fate. Design strategies. Protect from specific enzymes. DPP-4 resistance. Common modification. Enzyme inhibitors. Co-administration. Modulate metabolism.

Identificacion de metabolitos

Metabolites must be identified. Why. Safety assessment. Active metabolites. Toxic metabolites. Pharmacokinetics. Mass balance. Methods. In vitro systems. Plasma. Liver microsomes. S9 fraction. Hepatocytes. Kidney homogenate. In vivo studies. Animal species. Human. Sample collection. Plasma. Urine. Bile. Feces. Tissues. Analysis. LC-MS/MS. Full scan. Identification. MS-MS. Structure elucidation. HRMS. Accurate mass. Radiolabel studies. Mass balance. Distribution. Elimination. Metabolite profiling. Major metabolites. >10% exposure. Require characterization. Active metabolites. Pharmacological activity. May contribute. To effect. May require. Separate development. Toxic metabolites. Reactive species. Safety concern. Structural alerts. Human metabolites. May differ. From animals. MIST guidance. ICH M3. Metabolites in safety testing. Major human metabolites. Need exposure. In toxicology species. Or separate study. Metabolite identification is comprehensive. Essential for development. Guides safety strategy.

Factores que afectan metabolismo

Multiple factors influence metabolism. Sequence. Specificity for enzymes. Cleavage sites. Susceptibility. Structure. Conformational. Accessibility. Cyclization. Protects. Modifications. D-aminoacidos. Protease resistant. N-methylation. Blocks cleavage. PEGylation. Steric protection. Physiological. pH. Affects enzyme activity. Temperature. Reaction rate. Ionic strength. Enzyme activity. Biological. Species. Different enzymes. Different activities. Translatability. Disease state. Altered metabolism. Organ dysfunction. Renal impairment. Reduced clearance. Hepatic impairment. Altered metabolism. Age. Neonates different. Elderly different. Genetics. Polymorphisms. Enzyme variants. Interactions. Enzyme inhibitors. Co-administered drugs. Food effects. Formulation. Modified release. Alters exposure. Site of metabolism. Understanding factors. Enables prediction. Patient variability. Dosing adjustment. Drug interactions. Risk mitigation. Factors are multiple. Interconnected. Population variability. Clinical relevance. Must be assessed. For each peptide.

Estrategias de estabilizacion

Stabilization extends half-life. Sequence modification. Remove cleavage sites. DPP-4 prone sequences. Ala-Pro. Gly-Pro. Avoid or modify. D-aminoacido substitution. N-terminal modification. Cyclization. Head-to-tail. Side-chain. Disulfide. Protects termini. Conformational constraint. Reduced accessibility. Backbone modification. N-methylation. Beta-aminoacidos. Peptidomimetics. Not peptide. Different metabolism. Conjugation. PEGylation. Albumin binding. Fc fusion. Size increase. Steric protection. Reduced filtration. Reduced enzyme access. Formulation. Protease inhibitors. Co-formulated. Enteric coating. For oral. Protects from. Gastric enzymes. Route selection. SC vs IV. Different metabolism. First-pass avoidance. Tissue targeting. Local delivery. Reduce systemic exposure. Combination approaches. Often needed. Multiple strategies. Synergistic effect. Stabilization is balance. Activity retention. Safety profile. Cost of goods. Manufacturing complexity. Each approach. Has trade-offs. Optimal strategy. Peptide-specific. Application-specific. Stabilization extends exposure. Reduces dosing frequency. Improves therapeutic index. Patient convenience. Commercial viability.

Implicaciones para desarrollo

Metabolism affects development. Early assessment. In vitro stability. Identify liabilities. Guide design. Species selection. For toxicology. Metabolic similarity. To humans. PK prediction. Human PK. Allometric scaling. PBPK modeling. Metabolic data. Refines prediction. Safety evaluation. Metabolite safety. Reactive metabolites. Monitoring. Clinical development. PK studies. Metabolite measurement. Patient variability. Special populations. Dosing adjustments. Drug interactions. Metabolism-based. Enzyme inhibitors. Inducers. Regulatory. Metabolite identification. Safety testing. MIST guidance. Label claims. Metabolism effects. Drug interactions. Contraindications. Dosing recommendations. Metabolism is integral. To drug development. Informs design. Guides development. Supports safety. Enables prediction. Early understanding. Prevents failures. Later stages. Metabolism data. Are required. For approval. Must be comprehensive. Well-documented. Interpreted correctly. Integrated with. Other data. Clinical pharmacology. Toxicology. Clinical efficacy. Safety. Holistic view. Of drug behavior. In the body.

Hallazgos Clave

El metabolismo ocurre en sangre, higado, rinon y tejidos segun tamano y propiedades
Las principales enzimas incluyen DPP-4, ACE, NEP, aminopeptidasas y carboxipeptidasas
Los metabolitos mayores (>10% exposicion) requieren caracterizacion de seguridad
Secuencia, estructura, especie y enfermedad afectan metabolismo
La estabilizacion usa D-aa, ciclacion, PEGylation y modificacion de secuencia
Los datos metabolicos guian PK prediction, safety assessment y labeling

Más artículos en Metodología de Investigación

Más artículos en Información General

Términos del glosario

Metabolismo

Preguntas frecuentes

Que es el guidance MIST?: Metabolites In Safety Testing. ICH M3 guidance que establece cuando los metabolitos humanos mayores necesitan evaluacion de seguridad. Metabolitos >10% de exposicion de farmaco padre requieren consideracion. Si toxicologia en animales no cubre, puede requerir estudios especificos.
Como se identifica un metabolito activo?: Mediante testing de actividad biologica. Fracciones de plasma o muestras de pacientes se testean en el mismo ensayo que el farmaco padre. Si muestran actividad, se aísla y caracteriza el metabolito responsable. Se cuantifica su contribucion al efecto terapeutico.
Por que DPP-4 es problematica para algunos peptidos?: DPP-4 remueve dipeptidos del N-terminus de peptidos con Pro o Ala en posicion 2. GLP-1 y GIP son sustratos naturales, por lo que se degradan rapidamente. Para agonistas de GLP-1, la resistencia a DPP-4 es requisito para efecto terapeutico sostenido.
Que es un estudio de mass balance?: Estudio que administra farmaco radiomarcado (tipicamente C14) para rastrear distribucion, metabolismo y excrecion completa. Permite identificar todos los metabolitos y routes de eliminacion. Requerido para NDA. Confirmar que no hay acumulacion de metabolitos desconocidos.

Volver a la biblioteca de investigación